CHMP Reaffirms Backing of Leqembi Alzheimer's Drug
Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...
LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...
The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...
Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...
Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.
As a result, Oppenheimer anticipates some patients may switch from donanemab to Leqembi, especially with the availability of a subcutaneous (subQ) version. RBC Capital Markets says Biogen has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback